Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 6/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24880988 | 0.85 | GRM5 (0.39) | NR1H2USP2SMN1; SMN2PDK4GPR119 | |
| SCHEMBL12217740 | 0.83 | NR1H2 (0.48) | NR1H2USP2SMN1; SMN2PDK4GPR119 | |
| SCHEMBL31278957 | 0.81 | NR1H2 (0.36) | NR1H2USP2SMN1; SMN2PDK4GPR119 | |
| SCHEMBL25322440 | 0.79 | HPGD (0.38) | NR1H2USP2SMN1; SMN2PDK4GPR119 | |
| SCHEMBL31510697 | 0.78 | HPGD (0.40) | NR1H2USP2SMN1; SMN2PDK4GPR119 | |
| SCHEMBL23538445 | 0.76 | RORC (0.37) | NR1H2PDK4GPR119GRM5GRM1 | |
| SCHEMBL24881275 | 0.76 | NR1H2 (0.42) | NR1H2PDK4GPR119GRM5GRM1 | |
| SCHEMBL31434066 | 0.76 | NR1H2 (0.33) | NR1H2USP2SMN1; SMN2PDK4GPR119 | |
| SCHEMBL23538597 | 0.76 | USP30 (0.39) | NR1H2USP2SMN1; SMN2PDK4GRM5 | |
| SCHEMBL25453940 | 0.75 | NR1H2 (0.39) | NR1H2USP2SMN1; SMN2PDK4GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | NR1H2 3247/4885USP2 308/4885SMN1; SMN2 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.